CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Knowing when to update your personal budget is crucial for staying aligned with your financial goals. Explore the signs that indicate it's time for a revision.
19,364 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
SpaceX is courting attention ahead of a potential Nasdaq debut. Some ETFs offer pre-IPO exposure via SPVs, but the st...
A coalition of more than 200 crypto firms is urging lawmakers to pass the Digital Asset Market Clarity Act. If it bec...
When a company's CFO unloads thousands of shares, investors naturally ask what it means. This analysis dives into amb...
Investors dig into a mixed session as Amazon leads gains on Prime Day momentum and AI shopping activity. This guide b...
A domestic uranium producer is expanding beyond ore to processing key minerals. This article breaks down the strategy...
BYD again proves it can set records, this time overseas. The question for investors is how long that momentum lasts a...
Michael Burry’s shorts going strong have produced noticeable gains in select AI-adjacent bets, prompting a timely deb...
The first half of the year brought a sharp move for ServiceNow as AI expectations collided with reality. This article...
Wall Street is split on two big AI chips players: Intel and Marvell. One stock is riding optimism about data-center d...
What if SpaceX and xAI merged to run data centers in orbit? This article breaks down how orbital compute could work, ...
Intel stunned investors with a triple-digit rally in early 2026. This guide breaks down why intel stock soared 278%, ...